US20200101122A1 - Method for treating an auditory neuropathy spectrum disorder - Google Patents
Method for treating an auditory neuropathy spectrum disorder Download PDFInfo
- Publication number
- US20200101122A1 US20200101122A1 US16/586,768 US201916586768A US2020101122A1 US 20200101122 A1 US20200101122 A1 US 20200101122A1 US 201916586768 A US201916586768 A US 201916586768A US 2020101122 A1 US2020101122 A1 US 2020101122A1
- Authority
- US
- United States
- Prior art keywords
- pjvk
- aav
- vector
- promoter
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000002982 auditory neuropathy Diseases 0.000 title claims abstract description 34
- 208000020100 Auditory neuropathy spectrum disease Diseases 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 13
- 101100297725 Mus musculus Pjvk gene Proteins 0.000 claims abstract description 23
- 101001072259 Homo sapiens Protocadherin-15 Proteins 0.000 claims abstract description 17
- 102100036382 Protocadherin-15 Human genes 0.000 claims abstract description 17
- 241000702421 Dependoparvovirus Species 0.000 claims abstract description 15
- 239000013598 vector Substances 0.000 claims abstract description 15
- 108700019146 Transgenes Proteins 0.000 claims abstract description 14
- 102100040124 Apoptosis-inducing factor 1, mitochondrial Human genes 0.000 claims abstract description 6
- 102100037156 Gap junction beta-2 protein Human genes 0.000 claims abstract description 6
- 101000890622 Homo sapiens Apoptosis-inducing factor 1, mitochondrial Proteins 0.000 claims abstract description 6
- 101000954092 Homo sapiens Gap junction beta-2 protein Proteins 0.000 claims abstract description 6
- 101000928406 Homo sapiens Protein diaphanous homolog 3 Proteins 0.000 claims abstract description 6
- 101000735368 Homo sapiens Protocadherin-9 Proteins 0.000 claims abstract description 6
- 102100034198 Otoferlin Human genes 0.000 claims abstract description 6
- 102100036468 Protein diaphanous homolog 3 Human genes 0.000 claims abstract description 6
- 102100034957 Protocadherin-9 Human genes 0.000 claims abstract description 6
- 108091006282 SLC17A8 Proteins 0.000 claims abstract description 6
- 102100038033 Vesicular glutamate transporter 3 Human genes 0.000 claims abstract description 6
- 101001134169 Homo sapiens Otoferlin Proteins 0.000 claims abstract 3
- 210000003027 ear inner Anatomy 0.000 claims description 14
- 239000013607 AAV vector Substances 0.000 claims description 13
- 210000002768 hair cell Anatomy 0.000 claims description 9
- 102100024110 LHFPL tetraspan subfamily member 5 protein Human genes 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 5
- 210000000234 capsid Anatomy 0.000 claims description 4
- 108090000565 Capsid Proteins Proteins 0.000 claims description 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 3
- 102100031809 Espin Human genes 0.000 claims description 3
- 101710118108 Espin Proteins 0.000 claims description 3
- 101000981537 Homo sapiens LHFPL tetraspan subfamily member 5 protein Proteins 0.000 claims description 3
- 101000591234 Homo sapiens Phosphatidylinositol phosphatase PTPRQ Proteins 0.000 claims description 3
- 101000591236 Homo sapiens Receptor-type tyrosine-protein phosphatase R Proteins 0.000 claims description 3
- 101150050795 LHFPL5 gene Proteins 0.000 claims description 3
- 102100034101 Receptor-type tyrosine-protein phosphatase R Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 description 49
- 238000001415 gene therapy Methods 0.000 description 18
- 208000016354 hearing loss disease Diseases 0.000 description 15
- 230000035772 mutation Effects 0.000 description 14
- 206010011878 Deafness Diseases 0.000 description 13
- 230000006399 behavior Effects 0.000 description 12
- 230000013707 sensory perception of sound Effects 0.000 description 12
- 231100000888 hearing loss Toxicity 0.000 description 11
- 230000010370 hearing loss Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000009182 swimming Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000010825 rotarod performance test Methods 0.000 description 8
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 210000000133 brain stem Anatomy 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000005069 ears Anatomy 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000001720 vestibular Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000008447 perception Effects 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 230000005788 Cochlea function Effects 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000000860 cochlear nerve Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 210000001323 spiral ganglion Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 101150002843 Pjvk gene Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 210000003477 cochlea Anatomy 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000002985 organ of corti Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
- 206010011385 Cri-du-chat syndrome Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000001804 Monosomy 5p Diseases 0.000 description 2
- 208000006098 Neonatal Hyperbilirubinemia Diseases 0.000 description 2
- 201000006346 Neonatal Jaundice Diseases 0.000 description 2
- 102100036328 Pejvakin Human genes 0.000 description 2
- 101710135791 Pejvakin Proteins 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 201000008572 Usher syndrome type 1F Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003984 auditory pathway Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000000067 inner hair cell Anatomy 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150083557 Ear gene Proteins 0.000 description 1
- 102100039397 Gap junction beta-3 protein Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 229940123611 Genome editing Drugs 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 101000889136 Homo sapiens Gap junction beta-3 protein Proteins 0.000 description 1
- 101000635935 Homo sapiens Myosin-IIIa Proteins 0.000 description 1
- 101000572950 Homo sapiens POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 101000851696 Homo sapiens Steroid hormone receptor ERR2 Proteins 0.000 description 1
- 101000803332 Homo sapiens Wolframin Proteins 0.000 description 1
- 101150116611 LRRC51 gene Proteins 0.000 description 1
- 102100022186 Leucine-rich repeat-containing protein 51 Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102100030743 Myosin-IIIa Human genes 0.000 description 1
- 101150064891 PCDH15 gene Proteins 0.000 description 1
- 102000001675 Parvalbumin Human genes 0.000 description 1
- 108060005874 Parvalbumin Proteins 0.000 description 1
- 102100035278 Pendrin Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108091006507 SLC26A4 Proteins 0.000 description 1
- 102100036831 Steroid hormone receptor ERR2 Human genes 0.000 description 1
- 101150104365 Tomt gene Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100036022 Wolframin Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000017484 calcium-dependent cell-cell adhesion Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003952 cochlear nucleus Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000003552 inferior colliculi Anatomy 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000645 stria vascularis Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Definitions
- the present invention relates to a method for treating an auditory neuropathy spectrum disorder.
- SNHI severe to profound sensorineural hearing impairment
- ANSD is characterized by the preservation of normal outer hair cell function as evidenced by the presence of otoacoustic emissions (OAEs) and/or cochlear microphonics (CM), whereas the transmission of the auditory signal to the brainstem is impaired as evidenced by abnormal sound-evoked potentials of auditory brainstem response (ABR), poor speech perception and the absence of acoustic reflexes [3-5].
- OAEs otoacoustic emissions
- CM cochlear microphonics
- ABR auditory brainstem response
- the pathophysiology of ANSD has been proposed to involve an abnormal peripheral auditory system localized to the inner hair cells, the auditory nerve, or the synapse between them [6].
- ANSD might be caused by environmental insults, including infection during pregnancy, prematurity, perinatal hypoxemia and neonatal hyperbilirubinemia [7, 8], or it might be the consequence of certain syndromes, such as Charcot-Marie-Tooth disease [9] or cri-du-chat syndrome [10].
- the tendency of familial aggregation observed in some series suggests that genetic factors may also be involved in the pathogenesis [6-8]. It has been estimated that approximately 40% of ANSD cases may have a genetic basis [11].
- an auditory neuropathy spectrum disorder can be efficiently treated through a gene therapy via a vector comprising an Adeno-associated virus (AAV), called as an AAV vector hereinafter.
- AAV Adeno-associated virus
- the present invention provides a method for treating a method for treating an auditory neuropathy spectrum disorder in a subject comprising transferring a transgene via an adeno-associated virus (AAV) vector to the subject; wherein the transgene is selected from the group consisting of Pjvk, PCDH15, GJB2, DIAPH3, PCDH9, SLC17A8, AIFM1, and OTOF.
- AAV adeno-associated virus
- the present invention provides a construct for delivering a transgene to a subject suffering from an auditory neuropathy spectrum disorder, which comprises an adeno-associated virus (AAV) and the nucleic acids designated a transgene; wherein the transgene is selected from the group consisting of Pjvk, PCDH15, GJB2, DIAPH3, PCDH9, SLC17A8, AIFM1, and OTOF.
- AAV adeno-associated virus
- FIG. 1 provides the genes identified to be associated with good and poor CI outcomes.
- FIG. 2 provides an image of the auditory thresholds of Pjvk WT/WT and Pjvk G292R/G292R mice.
- FIG. 2(A) shows that ABR thresholds were measured in 3-week-old and 6-week-old mice.
- FIG. 2(B) shows that ABR traces (clicks-stimuli) at 100 dB SPL were superimposed (Pjvk WT/WT , black; Pjvk G292R/G292R , red).
- FIG. 3 shows the construct of an AAV vector containing the gene—Pjvk.
- FIG. 4 shows the ABR thresholds at 8, 16, and 32 kHz in Anc80L65.Pjvk—treated versus untreated Pjvk G292R/G292R mice.
- FIG. 5 provides the results of the Anc80-Pjvk gene therapy, showing that the circling behavior was reduced in treated mice.
- FIG. 6 provides the results of the Anc80-Pjvk gene therapy, showing that the rotarod performance was improves in treated mice.
- FIG. 7 provides the results of the Anc80-Pjvk gene therapy, showing that the swimming performance was improves in treated mice.
- Non-Syndromic Auditory neuropathy spectrum disorder (ANSD)
- SNHI severe to profound sensorineural hearing impairment
- ANSD is characterized by the preservation of normal outer hair cell function as evidenced by the presence of otoacoustic emissions (OAEs) and/or cochlear microphonics (CM), whereas the transmission of the auditory signal to the brainstem is impaired as evidenced by abnormal sound-evoked potentials of auditory brainstem response (ABR), poor speech perception and the absence of acoustic reflexes [3-5].
- OAEs otoacoustic emissions
- CM cochlear microphonics
- ABR auditory brainstem response
- the pathophysiology of ANSD has been proposed to involve an abnormal peripheral auditory system localized to the inner hair cells, the auditory nerve, or the synapse between them [6].
- ANSD might be caused by environmental insults, including infection during pregnancy, prematurity, perinatal hypoxemia and neonatal hyperbilirubinemia [7, 8], or it might be the consequence of certain syndromes, such as Charcot-Marie-Tooth disease [9] or cri-du-chat syndrome [10].
- the tendency of familial aggregation observed in some series suggests that genetic factors may also be involved in the pathogenesis [6-8]. It has been estimated that approximately 40% of ANSD cases may have a genetic basis [11].
- the hearing loss levels in patients with ANSD vary from mild to profound hearing loss, and their speech perception may be out of proportion to the audibility changes.
- patients with auditory neuropathy do not typically derive much benefit from hearing aids.
- Some of the patients are able to acquire speech and hearing without a hearing aid over time; some of them present well with hearing aids or cochlear implants (CIs); and still a part of them did not develop well in speech or hearing despite under CI use.
- Pjvk is a common cause of non-syndromic ANSD in humans. Delmaghani et al. identified mutations in the Pjvk gene in four familial cases of ANSD [12]. Two missense mutations were identified in the families.
- the Pjvk gene produces a protein the researchers named “pejvakin”, which is expressed in the organ of Corti, the spiral ganglion and the neuronal cell bodies of the cochlear nuclei, superior olivary complex and the inferior colliculus of the afferent auditory pathway. The researchers believe pejvakin is crucial for auditory nerve signalling. Mutation in this gene appears to result in auditory neuropathy due to a disruption in neuronal signalling along the auditory pathway. Cochlear function is intact in these patients.
- the PCDH15 gene is a member of the cadherin superfamily. Family members encode integral membrane proteins that mediate calcium-dependent cell-cell adhesion. it plays an essential role in maintenance of normal retinal and cochlear function. Mutations in this gene result in hearing loss and Usher Syndrome Type IF (USH1F). Extensive alternative splicing resulting in multiple isoforms has been observed in the mouse ortholog.
- AAV Adeno-Associated Virus
- Adeno-associated virus (AAV) vectors have emerged as a gene-delivery platform with demonstrated safety and efficacy in a handful of clinical trials for monogenic disorders.
- limitations of the current generation vectors often prevent broader application of AAV gene therapy.
- Efforts to engineer AAV vectors have been hampered by a limited understanding of the structure-function relationship of the complex multimeric icosahedral architecture of the particle.
- the AAV vector is an AAV vector comprising an Anc80 capsid protein as provided in WO2017/100791 A1, also called as an AAV-Anc80 vector.
- the AAV-Anc80 vector was confirmed to be able to efficiently deliver nucleic acids to the inner ear, e.g., cochlea, particularly the inner and outer hair cells (IHCs and OHCs) in the cochlea, which is an attractive target for gene therapy approaches to intervene in hearing loss and deafness of various etiologies, most immediately monogenic forms of inherited deafness.
- the AAV vector is a synthetic inner ear hair cell targeting adeno-associated virus (AAV) vector, wherein the vector encodes a capsid having at least about 85% sequence identity to Anc80, and comprises a promoter selected from the group consisting of an Espin promoter, a PCDH15 promoter, a PTPRQ promoter and a TMHS (LHFPL5) promoter that directs expression of harmonin-a, harmonin-b, or harmonin-c polypeptide, as provided in WO2018/145111 A1.
- AAV a synthetic inner ear hair cell targeting adeno-associated virus
- Genome-editing techniques were used to produce Pjvk p.G292R gene transgenic mice, in which the hearing characterization has been completed in the PjVk G292R/G292R mouse with the c.874 G>A mutation.
- Pjvk G2921/G292R mice showed significantly higher hearing thresholds than PjVk G292R/WT and Pjvk WT/WT mice at clicks, as well as 8 k, 16 k and 32 kHz pure tones on auditory brainstem response ( FIG. 2A ).
- Further analysis of the waveforms revealed prolonged latencies of all the ABR waves ( FIG. 2B ), indicating the presence of retrocochlear lesions.
- the full length sequence of Pjvk gene was cloned into the AAV expression vector.
- the construct can be co-transfected with the AAV-helpler plasmid (Anc80L65) into the HEK293 cells and produced the Anc80 virus particles.
- the construct of AAV-Pjvk was shown in FIG. 3 .
- a nanoliter microinjection system (Nanoliter2000; World Precision Instruments) was used to load Anc80L65.Pjvk into the glass micropipette (10 mm in diameter).
- a total of 0.7 ul Anc80L65.Pjvk was injected into round window membrane of inner ear of Pjvk p.G292R mice at P0-P3. Sham surgeries were performed as above with Anc80L65-GFP as a negative control virus.
- the treated mice showed lower auditory brainstem response thresholds and improved vestibular function as compared to the control group.
- the Anc80 virus particles were injected into the round window membrane by the microinjection.
- mice were anesthetized with sodium pentobarbital (35 mg/kg) delivered intraperitoneally and maintained in a head-holder within an acoustically and electrically insulated and grounded test room.
- We used an evoked potential detection system Smart EP 3.90, Intelligent Hearing Systems, Miami, Fla., USA to measure the thresholds of the auditory brainstem response (ABR) in mice.
- Click sounds as well as 8, 16, and 32 kHz tone bursts at varying intensity (from 10 to 130 dB SPL), were given to evoke ABRs of mice.
- the response signals were recorded with a subcutaneous needle electrode inserted ventrolaterally into the ears of the mice.
- the results of the gene therapy were shown in FIG. 4 , showing that the cochlear function was rescued.
- mice were subjected to a battery of vestibular evaluations, including observation of their circling behavior and head-tilting (performed at P90-120), a reaching test, a swimming test, and a rotarod test (all performed at P90-120 age).
- the reaching responses of mice were recorded after suspending animals by their tails and observing the reaction of their limbs and head-bobbing behaviors. Mice that extended their forelimbs and tried to reach a surface were considered normal (i.e., in terms of reaching response), whereas animals that either clasped their forelimbs or exhibited head-bobbing behavior were classified as abnormal.
- mice were observed for 15-20 s, and those that maintained themselves well at the water surface were classified as normal, whereas those that failed to stay near the surface were considered abnormal.
- mice were placed on the lower end of a 45-cm-long metal stick, and those that required more than 15 s to reach the top of the stick were classified as abnormal (i.e., ⁇ 15 s were normal).
- mice were assessed for their ability to balance on a revolving rod (i.e., rotarod) of 3.5 cm diameter. For each test, the mouse was placed on the rod rotating at 35 rpm, and the time required for the mouse to fall was recorded. Each mouse was tested 5 times, and the results were averaged.
- mice The circling behavior of mice was quantified using optical tracking.
- a 38-cm ⁇ 58-cm box was attached to a video camera (gopro).
- the ImageJ software was set to track the head of mice placed within the box.
- Each mouse was placed into the box and allowed to acclimate to the new environment for 2 min. Complete rotations were recorded and quantified for the next 2 min, followed by a 1-min “cool-down” period in which rotations were not tracked.
- Each mouse was assessed three times on the same day, and the average was taken.
- the Pjvk mutant mice had significant vestibule dysfunction, as evidenced by their circling behavior. It was confirmed that Anc80-Pjvk gene therapy reduced circling behavior in the mice treated with the gene therapy.
- the P90-120 mice was sent to the 30 sec-duration tracking of treated mice and untreated (mutant) control mice. The untreated mice had developed an obvious circling behavior and showed poor ability to reach the field boundary ( FIG. 5 , left). On the contrary, the treated mice did not show the circling behavior and could arrive the most boundary of the testing field without the interruption of moving direction by circling ( FIG. 5 , right).
- the rotarod test is a measure of balance function in which mice are placed on a rod that rotates with increasing velocity, and the length of time the mouse remaining balanced on the rotating rod is recorded.
- the Pjvk mutant mice also showed diminished balance on the rotarod test.
- the treated mice exhibited a better ability to stay on the rotating rod, and the untreated control mice showed a poor ability to stay on the rod with a shorter retaining time (65.1 ⁇ 13.1 sec) than the treated mice (213.4 ⁇ 12.3 sec), see Table 1 and FIG. 6 .
- mice were placed in a large container filled with room temperature water. Their swimming behavior was recorded using a video camera over 2 min. The videos were de-identified and scored by an observer who was blinded to the genotype and treatment and who was also not involved with the initial video recording. A well-established 0-3 scoring system was used to assess the swim performance. Briefly, a score of 0 indicates normal swimming behavior. A score of 1 indicates mild swimming abnormality (circling, vertical swimming). A score of 2 indicates moderate swimming abnormality (immobile floating). A score of 3 indicates significant swimming abnormality in which the mouse needs to be rescued immediately (underwater tumbling). swimming testing was performed at P90 ⁇ 120 in all animals (6 normal control mice, 8 untreated control mice, 8 mutant mice that received Anc80-Pjvk gene therapy and 5 mutant mice that received Anc80-GFP), see FIG. 7 .
- Tissues from inner ears of mice were subjected to hematoxylin and eosin (H&E) staining, and the morphology of each sample was examined with a Leica optical microscope.
- inner ears from adult mice were fixed by perilymphatic perfusion with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) through round and oval windows and a small fenestra in the apex of the cochlear bony capsule.
- PFA paraformaldehyde
- PBS phosphate-buffered saline
- Specimens were subsequently rinsed in PBS buffer and decalcified in 4% PFA with 0.35 M EDTA at 4° C. for 1 week.
- samples were dehydrated and embedded in paraffin. Subsequently, serial sections (7 ⁇ m) were stained with H&E.
- the tissues were mounted using the ProLong Antifade kit (Molecular Probes, Eugene, Oreg., USA) for 20 min at room temperature. Images of tissues were obtained using a laser scanning confocal microscope (Zeiss LSM 510, Germany).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention provides a method for treating a method for treating an auditory neuropathy spectrum disorder in a subject comprising transferring a transgene via an adeno-associated virus (AAV) vector to the subject; wherein the transgene is selected from the group consisting of Pjvk, PCDH15, GJB2, DIAPH3, PCDH9, SLC17A8, AIFM1, AND OTOF.
Description
- This non-provisional application claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62/737,406, filed on Sep. 27, 2018, all of which are hereby expressly incorporated by reference into the present application.
- The present invention relates to a method for treating an auditory neuropathy spectrum disorder.
- Hearing loss is the most common pediatric sensory defect: more than 1/1000 children are affected by severe to profound sensorineural hearing impairment (SNHI) [1]. Pediatric SNHI is composed of a plethora of disease entities. Among them, auditory neuropathy spectrum disorder (ANSD) is of special interest because of its unparalleled clinical manifestations. ANSD is not uncommon, accounting for approximately 7% of permanent childhood hearing loss and a significant (but as yet undetermined) proportion of adult impairment [2]. Patients with ANSD have various degrees of hearing loss with poor speech perception that is out of proportion to their hearing levels [3]. Audiologically, ANSD is characterized by the preservation of normal outer hair cell function as evidenced by the presence of otoacoustic emissions (OAEs) and/or cochlear microphonics (CM), whereas the transmission of the auditory signal to the brainstem is impaired as evidenced by abnormal sound-evoked potentials of auditory brainstem response (ABR), poor speech perception and the absence of acoustic reflexes [3-5]. The pathophysiology of ANSD has been proposed to involve an abnormal peripheral auditory system localized to the inner hair cells, the auditory nerve, or the synapse between them [6]. Etiologically, ANSD might be caused by environmental insults, including infection during pregnancy, prematurity, perinatal hypoxemia and neonatal hyperbilirubinemia [7, 8], or it might be the consequence of certain syndromes, such as Charcot-Marie-Tooth disease [9] or cri-du-chat syndrome [10]. The tendency of familial aggregation observed in some series suggests that genetic factors may also be involved in the pathogenesis [6-8]. It has been estimated that approximately 40% of ANSD cases may have a genetic basis [11].
- It is desirable to develop a new method for treating an auditory neuropathy spectrum disorder.
- It was unexpectedly discovered in the present invention that an auditory neuropathy spectrum disorder can be efficiently treated through a gene therapy via a vector comprising an Adeno-associated virus (AAV), called as an AAV vector hereinafter.
- The present invention provides a method for treating a method for treating an auditory neuropathy spectrum disorder in a subject comprising transferring a transgene via an adeno-associated virus (AAV) vector to the subject; wherein the transgene is selected from the group consisting of Pjvk, PCDH15, GJB2, DIAPH3, PCDH9, SLC17A8, AIFM1, and OTOF.
- In another aspect, the present invention provides a construct for delivering a transgene to a subject suffering from an auditory neuropathy spectrum disorder, which comprises an adeno-associated virus (AAV) and the nucleic acids designated a transgene; wherein the transgene is selected from the group consisting of Pjvk, PCDH15, GJB2, DIAPH3, PCDH9, SLC17A8, AIFM1, and OTOF.
- It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention.
- The patent or application file contains at least one color drawing. Copies of this patent or patent application publication with color drawing will be provided by the USPTO upon request and payment of the necessary fee.
- The drawings presenting the preferred embodiments of the present invention are aimed at explaining the present invention. It should be understood that the present invention is not limited to the preferred embodiments shown. The data in the figures and examples are shown as mean±standard deviation (SD). Significant differences are shown as follows: *p<0.05, ***p<0.001.
-
FIG. 1 provides the genes identified to be associated with good and poor CI outcomes. -
FIG. 2 provides an image of the auditory thresholds of PjvkWT/WT and PjvkG292R/G292R mice.FIG. 2(A) shows that ABR thresholds were measured in 3-week-old and 6-week-old mice. PjvkG292R/G292R mice (red) showed progressive severe hearing loss as compared to PjvkWT/WT mice (blue) at all frequencies (n=10 for each group; thresholds expressed in mean±SD).FIG. 2(B) shows that ABR traces (clicks-stimuli) at 100 dB SPL were superimposed (PjvkWT/WT, black; PjvkG292R/G292R, red). Note that wave I-V in 3-week-old PjvkG292R/G292R mice showed increased latencies and reduced peak amplitudes.FIG. 2(C) shows the patterns of parvalbumin immunolocalization in hair cells and spiral ganglion neurons of PjvkG292R/G292R mice. Degeneration of organ of Corti and spiral ganglion neurons are indicated by arrows and circles, respectively. (Bar=50 μm). -
FIG. 3 shows the construct of an AAV vector containing the gene—Pjvk. -
FIG. 4 shows the ABR thresholds at 8, 16, and 32 kHz in Anc80L65.Pjvk—treated versus untreated PjvkG292R/G292R mice. -
FIG. 5 provides the results of the Anc80-Pjvk gene therapy, showing that the circling behavior was reduced in treated mice. -
FIG. 6 provides the results of the Anc80-Pjvk gene therapy, showing that the rotarod performance was improves in treated mice. -
FIG. 7 provides the results of the Anc80-Pjvk gene therapy, showing that the swimming performance was improves in treated mice. - Unless otherwise defined herein, scientific and technical terms used herein have the meanings that are commonly understood by those of ordinary skill in the art.
- Hearing loss is the most common pediatric sensory defect: more than 1/1000 children are affected by severe to profound sensorineural hearing impairment (SNHI) [1]. Pediatric SNHI is composed of a plethora of disease entities. Among them, auditory neuropathy spectrum disorder (ANSD) is of special interest because of its unparalleled clinical manifestations. ANSD is not uncommon, accounting for approximately 7% of permanent childhood hearing loss and a significant (but as yet undetermined) proportion of adult impairment [2]. Patients with ANSD have various degrees of hearing loss with poor speech perception that is out of proportion to their hearing levels [3]. Audiologically, ANSD is characterized by the preservation of normal outer hair cell function as evidenced by the presence of otoacoustic emissions (OAEs) and/or cochlear microphonics (CM), whereas the transmission of the auditory signal to the brainstem is impaired as evidenced by abnormal sound-evoked potentials of auditory brainstem response (ABR), poor speech perception and the absence of acoustic reflexes [3-5]. The pathophysiology of ANSD has been proposed to involve an abnormal peripheral auditory system localized to the inner hair cells, the auditory nerve, or the synapse between them [6].
- Etiologically, ANSD might be caused by environmental insults, including infection during pregnancy, prematurity, perinatal hypoxemia and neonatal hyperbilirubinemia [7, 8], or it might be the consequence of certain syndromes, such as Charcot-Marie-Tooth disease [9] or cri-du-chat syndrome [10]. The tendency of familial aggregation observed in some series suggests that genetic factors may also be involved in the pathogenesis [6-8]. It has been estimated that approximately 40% of ANSD cases may have a genetic basis [11].
- The hearing loss levels in patients with ANSD vary from mild to profound hearing loss, and their speech perception may be out of proportion to the audibility changes. In addition, patients with auditory neuropathy do not typically derive much benefit from hearing aids. Some of the patients are able to acquire speech and hearing without a hearing aid over time; some of them present well with hearing aids or cochlear implants (CIs); and still a part of them did not develop well in speech or hearing despite under CI use. These features lead to difficulties in the diagnosis and treatment for patients with ANSD in clinical practice.
- Mutation in Pjvk is a common cause of non-syndromic ANSD in humans. Delmaghani et al. identified mutations in the Pjvk gene in four familial cases of ANSD [12]. Two missense mutations were identified in the families. The Pjvk gene produces a protein the researchers named “pejvakin”, which is expressed in the organ of Corti, the spiral ganglion and the neuronal cell bodies of the cochlear nuclei, superior olivary complex and the inferior colliculus of the afferent auditory pathway. The researchers believe pejvakin is crucial for auditory nerve signalling. Mutation in this gene appears to result in auditory neuropathy due to a disruption in neuronal signalling along the auditory pathway. Cochlear function is intact in these patients.
- The PCDH15 gene is a member of the cadherin superfamily. Family members encode integral membrane proteins that mediate calcium-dependent cell-cell adhesion. it plays an essential role in maintenance of normal retinal and cochlear function. Mutations in this gene result in hearing loss and Usher Syndrome Type IF (USH1F). Extensive alternative splicing resulting in multiple isoforms has been observed in the mouse ortholog.
- We identified patients with mutations in some genes, including Pjvk, PCDH15 GJB2, DIAPH3, PCDH9, SLC17A8, AIFM1, and OTOF, usually exhibit excellent long-term CI outcomes, probably because the effects of these mutations were confined to the inner ear and the function of the auditory nerve is spared. Based on the results of the clinical trial in multi-center studies for the purpose to identify the genetic determinants of poor CI outcomes in Taiwan, which enrolled more than 300 children with CIs, we identified genetic variants which are associated with poor CI outcomes in 7 (58%) of the 12 cases; 4 cases had bi-allelic PCDH15 pathogenic mutations and 3 cases were homozygous for the Pjvk p.G292R variant. Mutations in the WFS1, GJB3, ESRRB, LRTOMT, MYO3A, and POU3F4 genes were detected in 7 (23%) of the 30 matched controls. The allele frequencies of PCDH15 and Pjvkvariants were significantly higher in the cases than in the matched controls (both P<0.001). In the 7 CI recipients with PCDH15 or Pjvkvariants, otoacoustic emissions were absent in both ears, and imaging findings were normal in all 7 implanted ears. PCDH15 or Pjvkvariant is associated with poor CI performance, yet children with PCDH15 or Pjvkvariants might show clinical features indistinguishable from those of other typical pediatric CI recipients.
- 4. Adeno-Associated Virus (AAV)
- The use of viral vectors for inner ear gene therapy is receiving increased attention for treatment of genetic hearing disorders. Most animal studies to date have injected viral suspensions into neonatal ears, via the round window membrane. Achieving transduction of hair cells, or sensory neurons, throughout the cochlea has proven difficult, and no studies showed an efficient transduction of sensory cells in adult ears while maintaining normal cochlear functions [13].
- Adeno-associated virus (AAV) vectors have emerged as a gene-delivery platform with demonstrated safety and efficacy in a handful of clinical trials for monogenic disorders. However, limitations of the current generation vectors often prevent broader application of AAV gene therapy. Efforts to engineer AAV vectors have been hampered by a limited understanding of the structure-function relationship of the complex multimeric icosahedral architecture of the particle. To develop additional reagents pertinent to further our insight into AAVs, Luk H. Vandenberghe labortory inferred evolutionary intermediates of the viral capsid using ancestral sequence reconstruction. In-silico-derived sequences were synthesized de novo and characterized for biological properties relevant to clinical applications [14]. This effort led to the generation of nine functional putative ancestral AAVs and the identification of Anc80, the predicted ancestor of the widely studied
AAV serotypes - In one preferred embodiment of the invention, the AAV vector is an AAV vector comprising an Anc80 capsid protein as provided in WO2017/100791 A1, also called as an AAV-Anc80 vector. The AAV-Anc80 vector was confirmed to be able to efficiently deliver nucleic acids to the inner ear, e.g., cochlea, particularly the inner and outer hair cells (IHCs and OHCs) in the cochlea, which is an attractive target for gene therapy approaches to intervene in hearing loss and deafness of various etiologies, most immediately monogenic forms of inherited deafness.
- In one more preferred embodiment of the invention, the AAV vector is a synthetic inner ear hair cell targeting adeno-associated virus (AAV) vector, wherein the vector encodes a capsid having at least about 85% sequence identity to Anc80, and comprises a promoter selected from the group consisting of an Espin promoter, a PCDH15 promoter, a PTPRQ promoter and a TMHS (LHFPL5) promoter that directs expression of harmonin-a, harmonin-b, or harmonin-c polypeptide, as provided in WO2018/145111 A1.
- 5. Gene Therapy
- We have completed genetic studies in more than 250 patients with cochlear implantation. Mutations in most genes are related to good CI outcomes, but mutations in PCDH15 and Pjvk are associated with unfavorable CI outcomes (see
FIG. 1 ). Animal studies are currently underway to elucidate the pathogenetic mechanisms and to explore novel therapeutic approaches. Some genes have been identified to be associated with good and poor CI outcomes, as shown inFIG. 1 . - The invention is further illustrated by the following example, which should not be construed as further limiting.
- 1. Animal Model
- Genome-editing techniques were used to produce Pjvk p.G292R gene transgenic mice, in which the hearing characterization has been completed in the PjVkG292R/G292R mouse with the c.874 G>A mutation. PjvkG2921/G292R mice showed significantly higher hearing thresholds than PjVkG292R/WT and PjvkWT/WT mice at clicks, as well as 8 k, 16 k and 32 kHz pure tones on auditory brainstem response (
FIG. 2A ). Further analysis of the waveforms revealed prolonged latencies of all the ABR waves (FIG. 2B ), indicating the presence of retrocochlear lesions. In accordance with the audiological findings, pathological changes in hair cells and spiral ganglion neurons were observed in PjVkG2921/G292R mice at 1 Month (FIG. 2C ). In addition to the hearing phenotypes, PjvkG2921/G292R mice also demonstrated equilibrium deficits suggesting pathologies involving both the vestibular organ (circling) and the central nervous system (nodding). - 2. Gene Therapy
- The full length sequence of Pjvk gene was cloned into the AAV expression vector. The construct can be co-transfected with the AAV-helpler plasmid (Anc80L65) into the HEK293 cells and produced the Anc80 virus particles. The construct of AAV-Pjvk was shown in
FIG. 3 . - A nanoliter microinjection system (Nanoliter2000; World Precision Instruments) was used to load Anc80L65.Pjvk into the glass micropipette (10 mm in diameter). A total of 0.7 ul Anc80L65.Pjvk was injected into round window membrane of inner ear of Pjvk p.G292R mice at P0-P3. Sham surgeries were performed as above with Anc80L65-GFP as a negative control virus. At P45, the treated mice showed lower auditory brainstem response thresholds and improved vestibular function as compared to the control group. The findings suggested that the Anc80-directed gene therapy was an efficient delivery system for simultaneously introducing genes to both the sensory cells of the inner ear and the neurons of the central auditory/vestibular pathways.
- The Anc80 virus particles were injected into the round window membrane by the microinjection.
- 3. Audiological Evaluations
- Mice were anesthetized with sodium pentobarbital (35 mg/kg) delivered intraperitoneally and maintained in a head-holder within an acoustically and electrically insulated and grounded test room. We used an evoked potential detection system (Smart EP 3.90, Intelligent Hearing Systems, Miami, Fla., USA) to measure the thresholds of the auditory brainstem response (ABR) in mice. Click sounds as well as 8, 16, and 32 kHz tone bursts at varying intensity (from 10 to 130 dB SPL), were given to evoke ABRs of mice. The response signals were recorded with a subcutaneous needle electrode inserted ventrolaterally into the ears of the mice.
- The results of the gene therapy were shown in
FIG. 4 , showing that the cochlear function was rescued. The PjvkG2921/G292R mice treated with an AAV vector comprising Anc80 (Anc80-Pjvk) provided lower ABR thresholds measured at 6 weeks showed improved hearing thresholds in the treated ears as compared with the untreated mice, especially at 8, 16 and 32 kHz. - 4. Vestibular Evaluations
- Mice were subjected to a battery of vestibular evaluations, including observation of their circling behavior and head-tilting (performed at P90-120), a reaching test, a swimming test, and a rotarod test (all performed at P90-120 age). The reaching responses of mice were recorded after suspending animals by their tails and observing the reaction of their limbs and head-bobbing behaviors. Mice that extended their forelimbs and tried to reach a surface were considered normal (i.e., in terms of reaching response), whereas animals that either clasped their forelimbs or exhibited head-bobbing behavior were classified as abnormal. For the swimming test, mice were observed for 15-20 s, and those that maintained themselves well at the water surface were classified as normal, whereas those that failed to stay near the surface were considered abnormal. For the gripping test, mice were placed on the lower end of a 45-cm-long metal stick, and those that required more than 15 s to reach the top of the stick were classified as abnormal (i.e., <15 s were normal). For the rotarod test, mice were assessed for their ability to balance on a revolving rod (i.e., rotarod) of 3.5 cm diameter. For each test, the mouse was placed on the rod rotating at 35 rpm, and the time required for the mouse to fall was recorded. Each mouse was tested 5 times, and the results were averaged.
- 5. Circling Behavior
- The circling behavior of mice was quantified using optical tracking. A 38-cm×58-cm box was attached to a video camera (gopro). The ImageJ software was set to track the head of mice placed within the box. Each mouse was placed into the box and allowed to acclimate to the new environment for 2 min. Complete rotations were recorded and quantified for the next 2 min, followed by a 1-min “cool-down” period in which rotations were not tracked. Each mouse was assessed three times on the same day, and the average was taken.
- As shown in
FIG. 5 , the Pjvk mutant mice had significant vestibule dysfunction, as evidenced by their circling behavior. It was confirmed that Anc80-Pjvk gene therapy reduced circling behavior in the mice treated with the gene therapy. After the gene therapy, the P90-120 mice was sent to the 30 sec-duration tracking of treated mice and untreated (mutant) control mice. The untreated mice had developed an obvious circling behavior and showed poor ability to reach the field boundary (FIG. 5 , left). On the contrary, the treated mice did not show the circling behavior and could arrive the most boundary of the testing field without the interruption of moving direction by circling (FIG. 5 , right). - It was also confirmed in the rotarod test that the gene therapy improved the balance function in rotarod test. The rotarod test is a measure of balance function in which mice are placed on a rod that rotates with increasing velocity, and the length of time the mouse remaining balanced on the rotating rod is recorded. The Pjvk mutant mice also showed diminished balance on the rotarod test. After gene therapy, the treated mice exhibited a better ability to stay on the rotating rod, and the untreated control mice showed a poor ability to stay on the rod with a shorter retaining time (65.1±13.1 sec) than the treated mice (213.4 ±12.3 sec), see Table 1 and
FIG. 6 . -
TABLE 1 The result of rotarod test at P90~120 Pjvk Pjvk Pjvk Normal untreated treated w/ treated w/ control control Anc80-Pjvk Anc80-GFP (n = 6) (n = 8) (n = 8) (n = 5) Time on 213.2 ± 7.2 65.1 ± 13.1 213.4 ± 12.3 79.4 ± 7.7 rod (sec) - 6. Swim Testing
- Mice were placed in a large container filled with room temperature water. Their swimming behavior was recorded using a video camera over 2 min. The videos were de-identified and scored by an observer who was blinded to the genotype and treatment and who was also not involved with the initial video recording. A well-established 0-3 scoring system was used to assess the swim performance. Briefly, a score of 0 indicates normal swimming behavior. A score of 1 indicates mild swimming abnormality (circling, vertical swimming). A score of 2 indicates moderate swimming abnormality (immobile floating). A score of 3 indicates significant swimming abnormality in which the mouse needs to be rescued immediately (underwater tumbling). Swimming testing was performed at P90˜120 in all animals (6 normal control mice, 8 untreated control mice, 8 mutant mice that received Anc80-Pjvk gene therapy and 5 mutant mice that received Anc80-GFP), see
FIG. 7 . - 7. Inner Ear Morphology Studies
- Tissues from inner ears of mice were subjected to hematoxylin and eosin (H&E) staining, and the morphology of each sample was examined with a Leica optical microscope. For light microscopy, inner ears from adult mice were fixed by perilymphatic perfusion with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) through round and oval windows and a small fenestra in the apex of the cochlear bony capsule. Specimens were subsequently rinsed in PBS buffer and decalcified in 4% PFA with 0.35 M EDTA at 4° C. for 1 week. For light microscopy studies, samples were dehydrated and embedded in paraffin. Subsequently, serial sections (7 μm) were stained with H&E.
- Whole-mount studies of mouse inner ear specimens were performed as previously described
- with some minor modification. Briefly, after perfusion with 4% PFA, the cochleae were postfixed in the same solution for 2 h at room temperature and washed in PBS. Segments of stria vascularis and organ of Corti together with Reissner's membrane were dissected out of the inner ear specimens using a fine needle. Samples were permeabilized in 1% Triton X-100 for 30 min and washed with PBS, followed by overnight incubation at 4° C. in blocking solution. The tissues were then stained with rhodamine-phalloidin (1:100 dilution; Molecular Probes, Eugene, Oreg., USA). After washing in PBS, the tissues were mounted using the ProLong Antifade kit (Molecular Probes, Eugene, Oreg., USA) for 20 min at room temperature. Images of tissues were obtained using a laser scanning confocal microscope (Zeiss LSM 510, Germany).
- While the present invention has been disclosed by way preferred embodiments, it is not intended to limit the present invention. Any person of ordinary skill in the art may, without departing from the spirit and scope of the present invention, shall be allowed to perform modification and embellishment. Therefore, the scope of protection of the present invention shall be governed by which defined by the claims attached subsequently.
- [1] J. B. Nadol, Jr., Hearing loss, N Engl J Med 329(15) (1993) 1092-102.
- [2] G. Rance, Auditory neuropathy/dys-synchrony and its perceptual consequences, Trends Amplif 9(1) (2005) 1-43.
- [3] A. Starr, T. W. Picton, Y. Sininger, L. J. Hood, C. I. Berlin, Auditory neuropathy, Brain 119 (Pt 3) (1996) 741-53.
- [4] G. Rance, D. E. Beer, B. Cone-Wesson, R. K. Shepherd, R. C. Dowell, A. M. King, F. W. Rickards, G. M. Clark, Clinical findings for a group of infants and young children with auditory neuropathy, Ear Hear 20(3) (1999) 238-52.
- [5] M. Rodriguez-Ballesteros, R. Reynoso, M. Olarte, M. Villamar, C. Morera, R. Santarelli, E. Arslan, C. Meda, C. Curet, C. Volter, M. Sainz-Quevedo, P. Castorina, U. Ambrosetti, S. Berrettini, K. Frei, S. Tedin, J. Smith, M. Cruz Tapia, L. Cavalle, N. Gelvez, P. Primignani, E. Gomez-Rosas, M. Martin, M. A. Moreno-Pelayo, M. Tamayo, J. Moreno-Barral, F. Moreno, I. del Castillo, A multicenter study on the prevalence and spectrum of mutations in the otoferlin gene (OTOF) in subjects with nonsyndromic hearing impairment and auditory neuropathy, Hum Mutat 29(6) (2008) 823-31.
- [6] A. Starr, Y. S. Sininger, H. Pratt, The varieties of auditory neuropathy, J Basic Clin Physiol Pharmacol 11(3) (2000) 215-30.
- [7] D. Beutner, A. Foerst, R. Lang-Roth, H. von Wedel, M. Walger, Risk factors for auditory neuropathy/auditory synaptopathy, ORL J Otorhinolaryngol Relat Spec 69(4) (2007) 239-44.
- [8] C. Madden, M. Rutter, L. Hilbert, J. H. Greinwald, Jr., D. I. Choo, Clinical and audiological features in auditory neuropathy, Arch Otolaryngol Head Neck Surg 128(9) (2002) 1026-30.
- [9] H. Perez, J. Vilchez, T. Sevilla, L. Martinez, Audiologic evaluation in Charcot-Marie-Tooth disease, Scand Audiol Suppl 30 (1988) 211-3.
- [10] D. Swanepoel, Auditory pathology in cri-du-chat (5p−) syndrome: phenotypic evidence for auditory neuropathy, Clin Genet 72(4) (2007) 369-73.
- [11] V. K. Manchaiah, F. Zhao, A. A. Danesh, R. Duprey, The genetic basis of auditory neuropathy spectrum disorder (ANSD), Int J Pediatr Otorhinolaryngol 75(2) (2011) 151-8.
- [12] S. Delmaghani, F. J. del Castillo, V. Michel, M. Leibovici, A. Aghaie, U. Ron, L. Van Laer, N. Ben-Tal, G. Van Camp, D. Weil, F. Langa, M. Lathrop, P. Avan, C. Petit, Mutations in the gene encoding pejvakin, a newly identified protein of the afferent auditory pathway, cause DFNB59 auditory neuropathy, Nat Genet 38(7) (2006) 770-8.
- [13] J. Suzuki, K. Hashimoto, R. Xiao, L. H. Vandenberghe, M. C. Liberman, Cochlear gene therapy with ancestral AAV in adult mice: complete transduction of inner hair cells without cochlear dysfunction, Sci Rep 7 (2017) 45524.
- [14] E. Zinn, S. Pacouret, V. Khaychuk, H. T. Turunen, L. S. Carvalho, E. Andres-Mateos, S. Shah, R. Shelke, A. C. Maurer, E. Plovie, R. Xiao, L. H. Vandenberghe, In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector, Cell Rep 12(6) (2015) 1056-68.
- [15] L. D. Landegger, B. Pan, C. Askew, S. J. Wassmer, S. D. Gluck, A. Galvin, R. Taylor, A. Forge, K. M. Stankovic, J. R. Holt, L. H. Vandenberghe, A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear, Nat Biotechnol 35(3) (2017) 280-284.
- [] Y. C. Lu, C. C. Wu, W. S. Shen, T. H. Yang, T. H. Yeh, P. J. Chen, I. S. Yu, S. W. Lin, J. M. Wong, Q. Chang, X. Lin, C. J. Hsu, Establishment of a Knock-In Mouse Model with the SLC26A4 c.919-2A>G Mutation and Characterization of Its Pathology, Plos One 6(7) (2011).
Claims (8)
1. A method for treating a method for treating an auditory neuropathy spectrum disorder in a subject comprising transferring a transgene via an adeno-associated virus (AAV) vector to the subject; wherein the transgene is selected from the group consisting of Pjvk, PCDH15, GJB2, DIAPH3, PCDH9, SLC17A8, AIFM1, and OTOF.
2. The method of claim 1 , wherein the transgene is Pjvk or PCDH15.
3. The method of claim 1 , wherein the AAV vector is an AAV vector comprising an Anc80 capsid protein.
4. The method of claim 3 , wherein the AAV vector is a synthetic inner ear hair cell targeting adeno-associated virus (AAV) vector, wherein the vector encodes a capsid having at least about 85% sequence identity to Anc80, and comprises a promoter selected from the group consisting of an Espin promoter, a PCDH15 promoter, a PTPRQ promoter and a TMHS (LHFPL5) promoter that directs expression of harmonin-a, harmonin-b, or harmonin-c polypeptide.
5. A construct for delivering a transgene to a subject suffering from an auditory neuropathy spectrum disorder, which comprises an adeno-associated virus (AAV) and the nucleic acids designated a transgene;
wherein the transgene is selected from the group consisting of Pjvk, PCDH15, GJB2, DIAPH3, PCDH9, SLC17A8, AIFM1, and OTOF.
6. The construct of claim 5 , wherein the transgene is Pjvk or PCDH15.
7. The construct of claim 5 , wherein the AAV vector is an AAV vector comprising an Anc80 capsid protein.
8. The construct of claim 7 , wherein the AAV vector is a synthetic inner ear hair cell targeting adeno-associated virus (AAV) vector, wherein the vector encodes a capsid having at least about 85% sequence identity to Anc80, and comprises a promoter selected from the group consisting of an Espin promoter, a PCDH15 promoter, a PTPRQ promoter and a TMHS (LHFPL5) promoter that directs expression of harmonin-a, harmonin-b, or harmonin-c polypeptide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/586,768 US20200101122A1 (en) | 2018-09-27 | 2019-09-27 | Method for treating an auditory neuropathy spectrum disorder |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862737406P | 2018-09-27 | 2018-09-27 | |
US16/586,768 US20200101122A1 (en) | 2018-09-27 | 2019-09-27 | Method for treating an auditory neuropathy spectrum disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200101122A1 true US20200101122A1 (en) | 2020-04-02 |
Family
ID=69945592
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/586,768 Abandoned US20200101122A1 (en) | 2018-09-27 | 2019-09-27 | Method for treating an auditory neuropathy spectrum disorder |
US17/280,786 Pending US20220000972A1 (en) | 2018-09-27 | 2019-09-27 | A method for treating an auditory neuropathy spectrum disorder |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/280,786 Pending US20220000972A1 (en) | 2018-09-27 | 2019-09-27 | A method for treating an auditory neuropathy spectrum disorder |
Country Status (4)
Country | Link |
---|---|
US (2) | US20200101122A1 (en) |
EP (1) | EP3856227A4 (en) |
TW (1) | TW202027778A (en) |
WO (1) | WO2020069320A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11525139B2 (en) | 2016-08-23 | 2022-12-13 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
US11807867B2 (en) | 2020-02-21 | 2023-11-07 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102864216A (en) * | 2012-05-29 | 2013-01-09 | 王秋菊 | Kit for detecting c.886C>T mutation of PJVK gene |
WO2016131981A1 (en) * | 2015-02-20 | 2016-08-25 | Institut Pasteur | Prevention and/or treatment of hearing loss or impairment |
WO2017100791A1 (en) * | 2015-12-11 | 2017-06-15 | Massachusetts Eye And Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102747146A (en) | 2012-05-29 | 2012-10-24 | 王秋菊 | Kit for detecting PJVK gene c.887G>A mutation |
WO2018145111A1 (en) | 2017-02-06 | 2018-08-09 | Children's Medical Center Corporation | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
-
2019
- 2019-09-27 WO PCT/US2019/053465 patent/WO2020069320A1/en unknown
- 2019-09-27 US US16/586,768 patent/US20200101122A1/en not_active Abandoned
- 2019-09-27 EP EP19866960.8A patent/EP3856227A4/en active Pending
- 2019-09-27 US US17/280,786 patent/US20220000972A1/en active Pending
- 2019-09-27 TW TW108135364A patent/TW202027778A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102864216A (en) * | 2012-05-29 | 2013-01-09 | 王秋菊 | Kit for detecting c.886C>T mutation of PJVK gene |
WO2016131981A1 (en) * | 2015-02-20 | 2016-08-25 | Institut Pasteur | Prevention and/or treatment of hearing loss or impairment |
WO2017100791A1 (en) * | 2015-12-11 | 2017-06-15 | Massachusetts Eye And Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
Non-Patent Citations (3)
Title |
---|
Homo sapiens pejvakin (PJVK), transcript variant 1, mRNA, NCBI Reference Sequence: NM_001042702.5, accessed ad retrieved from ncbi.nlm.nih.gov on April 12, 2023. total 7 pages. (Year: 2023) * |
Homo sapiens pejvakin (PJVK), transcript variant 2, mRNA, NCBI Reference Sequence: NM_001353775.2, accessed ad retrieved from ncbi.nlm.nih.gov on April 12, 2023. total 7 pages. (Year: 2023) * |
Mus musculus pejvakin (Pjvk), mRNA, NCBI Reference Sequence: NM_001080711.2, accessed ad retrieved from ncbi.nlm.nih.gov on April 12, 2023. total 5 pages. (Year: 2023) * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11525139B2 (en) | 2016-08-23 | 2022-12-13 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
US11781145B2 (en) | 2016-08-23 | 2023-10-10 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
US11993777B2 (en) | 2016-08-23 | 2024-05-28 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
US11807867B2 (en) | 2020-02-21 | 2023-11-07 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
Also Published As
Publication number | Publication date |
---|---|
WO2020069320A4 (en) | 2020-06-18 |
WO2020069320A1 (en) | 2020-04-02 |
TW202027778A (en) | 2020-08-01 |
EP3856227A1 (en) | 2021-08-04 |
US20220000972A1 (en) | 2022-01-06 |
EP3856227A4 (en) | 2022-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109310745B (en) | Materials and methods for delivery of nucleic acids to cochlear and vestibular cells | |
Geng et al. | Modeling and preventing progressive hearing loss in Usher syndrome III | |
US20230330268A1 (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
Rankovic et al. | Overloaded adeno-associated virus as a novel gene therapeutic tool for otoferlin-related deafness | |
US20200392516A1 (en) | Compositions and methods for delivering nucleic acids to cochlear and vestibular cells | |
US20200114023A1 (en) | Gene therapy constructs and methods for treatment of hearing loss | |
Longo-Guess et al. | A missense mutation in the conserved C2B domain of otoferlin causes deafness in a new mouse model of DFNB9 | |
US20200101122A1 (en) | Method for treating an auditory neuropathy spectrum disorder | |
Akil et al. | Virally mediated overexpression of glial-derived neurotrophic factor elicits age-and dose-dependent neuronal toxicity and hearing loss | |
Lu et al. | Gene therapy with a synthetic adeno-associated viral vector improves audiovestibular phenotypes in Pjvk-mutant mice | |
CN113825521A (en) | Adeno-associated virus and its use for inner ear therapy | |
Ross et al. | Outer retinal transduction by AAV2-7m8 following intravitreal injection in a sheep model of CNGA3 achromatopsia | |
CN113840915A (en) | Adeno-associated virus and its use for inner ear therapy | |
Lahlou et al. | Extended time frame for restoring inner ear function through gene therapy in Usher1G preclinical model | |
US20200181596A1 (en) | Gene therapy systems and related methods for treatment of hearing loss | |
JP2023513116A (en) | Gene therapy system and related methods for the treatment of hearing loss | |
JP2024518552A (en) | Gene therapy constructs and methods for treating hearing loss - Patents.com | |
Koleilat | Zebrafish Hearing Science: Paving the Way to Better Patient Care | |
van Looij | Hearing loss in HDR syndrome: a study of mice and men | |
JP2017025008A (en) | Treatment of retinitis pigmentosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |